
ADC Innovations With T-DXd/Sacituzumab Govitecan in Breast Cancer
The landscape of breast cancer treatment is undergoing a significant evolution marked by the emergence of sophisticated targeted therapies. Among these options, antibody-drug conjugates (ADCs) like fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) and …